Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
= 17 mei de dag van de waarheid?
Volgen
marlanki schreef op 15 mei 2017 13:29 :
[...]
Vast wel. Komt goed met Pharming. Ben ik van overtuigd.
1e kwartaalcijfers woensdagmorgen zullen aangeven dat directie van Pharming de juiste stap heeft gezet door terugkoop verkooprechten Ruconest in Noord-Amerika van Valeant. Kostte een paar centjes, maar dan heb je ook wat (terug).
Heb daarom nog wat bijgekocht.
Leuk hoor marlanki: "het kostte een paar centen". Was dat maar waar.Het kost (tegenwoordige tijd,je weet wel)voorlopig nog heel wat centen.En ook nog jaren aan afromen resultaat!. Daarom moet woensdag het verhaal er wel goed uit zien!.
Ik hoop het ook marlanki maar die stilte vertrouw ik niet helemaal.
twopence schreef op 15 mei 2017 13:39 :
Ik hoop het ook marlanki maar die stilte vertrouw ik niet helemaal.
Sinds jaar en dag is De Vries niet bepaald scheutig met persberichten. Jammer. Alleen nieuws wat er echt toe doet, brengt hij naar buiten. We zullen dus moeten wachten op nieuws en op de (kwartaal)cijfers. In ieder geval weten we woensdagmorgen iets meer.
woensdag moeten we alleen cijfers krijgen die tonen dat we op de goede weg zijn de nieuwe verkoopstrategie moet ook tijd hebben om zich in te werken. als dat zo is verwacht ik toch een .45. het tweede kwartaal moet echter bevestigen dat de nieuwe verkoopstrategie goed werkt en dan kan de koers alleen maar hoger. ik heb er vertrouwen in dat we met pharming eindelijk het verleden achter ons kunnen laten.
hogere koersen zal het aandeel beter beschermen tegen de daytraders.
husa schreef op 15 mei 2017 17:18 :
hogere koersen zal het aandeel beter beschermen tegen de daytraders.
Ik verwacht morgen al een eerste stijging van de koers. Vandaag maar zeer kleine omzet tot nu toe. Slechts 1,8 miljoen stukjes over en weer verhandeld.
marlanki schreef op 15 mei 2017 17:25 :
[...]
Ik verwacht morgen al een eerste stijging van de koers. Vandaag maar zeer kleine omzet tot nu toe. Slechts 1,8 miljoen stukjes over en weer verhandeld.
Velen hadden eerder een hogere stijging verwacht waaronder mijzelf.
twopence schreef op 15 mei 2017 21:59 :
[...]
Velen hadden eerder een hogere stijging verwacht waaronder mijzelf.
Doe niet zo naïef! De stijging is al geweest en brengt niets meer ........ Alleen de hele groten hebben de winst weer binnen...... Dus jullie praat hier slaat helemaaaaal nergens op...... Naïevelingen!
Dennis V. schreef op 14 mei 2017 09:46 :
Nu blijven zitten, is de beste optie!
Zoals ik al eerder zei!
A global awareness day for a rare life-threatening condition: World HAEday, 16th May 2017 Leiden, The Netherlands, 16 May 2017: On May the 16th Hereditary Angioedema (HAE) patient organizationsfrom around the world, led by HAEi ( The international HAE patient organisation) come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition. “haeday:)” aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need to lead a healthy life. Dr Sijmen de Vries, Pharming’s CEO commented: "We are proud to provide the first and only recombinant (C1- esterase inhibitor) protein replacement therapy for the treatment of acute angioedema attacks in adults and adolescents with HAE. Pharming has been collaborating with the HAE community since 2000. We are delighted to support this year's haeday:) and are dedicated to continue making a difference in patients' and their families' lives, working in close partnership with HAEi and its local affiliates." “HAE is a rare genetic disorder that causes attacks involving swelling to various parts of the body, and can be fatal when the swelling affects the throat due to the risk of suffocation”, explains Mr. Henrik Balle Boysen, Executive Director of HAEi, the international patient organization leading the day: “Global awareness initiatives such as the haeday:) are necessary in order to help patients receive faster diagnosis and care to manage the disease.” As part of the awareness initiatives, HAEi introduces “Support Family Testing” tools on the organization’s campaign website www.haeday.org “As HAE is an hereditary disorder, it is very important to have other family members tested. To help patients in this process we have developed two documents, one for patients and one for physicians”, says Henrik Balle Boysen. HAEi is a global organization dedicated to raising awareness of C1 inhibitor deficiencies, as HAE patients have a defect in the gene that controls C1INH, and so the disorder is also commonly referred to as C1-inhibitor deficiency. HAEi is a non-profit international network of 55 national HAE patient organizations at present, spread across the globe. “HAEi has been established to promote co-operation, co-ordination and information-sharing between HAE specialists and national HAE patient associations to help facilitate the availability of effective diagnosis and management of C1 inhibitor deficiencies throughout the world. Our purpose is to join the efforts and experience of the global HAE community to achieve optimal standards of care and treatment for all those patients affected by C1 inhibitor deficiencies”, says Mr. Balle Boysen. 2 The main symptom of HAE is swelling of the body tissues, which doctors call “edema”, occurring mainly in the face (e.g. lips, eyelids), although the extremities and genitals are often affected. Swelling of the internal organs, specifically the mucous membranes of the larynx, nose or tongue, is potentially life threatening as it can cause death by suffocation. More than 50 per cent of HAE patients will experience at least one attack of this type in their lifetime. “Patients are frequently misdiagnosed because HAE symptoms often resemble those of more common conditions. Through 2017 haeday:) we hope to spread the word about HAE, so patients can receive an accurate diagnosis and appropriate medical care,” Mr. Balle Boysen explains: “We are very excited by the level of participation from the HAE national organizations across the globe and hope that the awareness day will make a real difference to lives of HAE patients in the future.” HAE places extraordinary strain on patients, often restricting their ability to lead normal lives. Untreated HAE patients can lose 100 to 150 workdays per year or more. Currently there is no permanent cure for HAE, but treatment options are available to try and prevent attacks from occurring or to treat attacks when they do occur. Various events are taking place across the globe in aid of the global awareness day. Internationally 2017 haeday:) coincides with some 30 patients and supporters – many of who suffer with from HAE – from Africa, Europe, North America, and South America walking part of the historic Camino de Santiago in northern Spain 14-17 May 2017. • Join the official haeday:) o Website at www.haeday.org o Facebook page at www.facebook.com/haeday o Twitter account at www.twitter.com/haeday o YouTube channel at www.youtube.com/haedaychannel • Other sources o HAEi website: www.haei.org o HAE QE (Nederlandse HAE patiënten vereniging) www.hae-qe.nl/
A global awareness day for a rare life-threatening condition: World HAEday, 16th May 2017 Leiden, The Netherlands, 16 May 2017: On May the 16th Hereditary Angioedema (HAE) patient organizationsfrom around the world, led by HAEi ( The international HAE patient organisation) come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition. “haeday:)” aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need to lead a healthy life. Dr Sijmen de Vries, Pharming’s CEO commented: "We are proud to provide the first and only recombinant (C1- esterase inhibitor) protein replacement therapy for the treatment of acute angioedema attacks in adults and adolescents with HAE. Pharming has been collaborating with the HAE community since 2000. We are delighted to support this year's haeday:) and are dedicated to continue making a difference in patients' and their families' lives, working in close partnership with HAEi and its local affiliates." “HAE is a rare genetic disorder that causes attacks involving swelling to various parts of the body, and can be fatal when the swelling affects the throat due to the risk of suffocation”, explains Mr. Henrik Balle Boysen, Executive Director of HAEi, the international patient organization leading the day: “Global awareness initiatives such as the haeday:) are necessary in order to help patients receive faster diagnosis and care to manage the disease.” As part of the awareness initiatives, HAEi introduces “Support Family Testing” tools on the organization’s campaign website www.haeday.org “As HAE is an hereditary disorder, it is very important to have other family members tested. To help patients in this process we have developed two documents, one for patients and one for physicians”, says Henrik Balle Boysen. HAEi is a global organization dedicated to raising awareness of C1 inhibitor deficiencies, as HAE patients have a defect in the gene that controls C1INH, and so the disorder is also commonly referred to as C1-inhibitor deficiency. HAEi is a non-profit international network of 55 national HAE patient organizations at present, spread across the globe. “HAEi has been established to promote co-operation, co-ordination and information-sharing between HAE specialists and national HAE patient associations to help facilitate the availability of effective diagnosis and management of C1 inhibitor deficiencies throughout the world. Our purpose is to join the efforts and experience of the global HAE community to achieve optimal standards of care and treatment for all those patients affected by C1 inhibitor deficiencies”, says Mr. Balle Boysen. 2 The main symptom of HAE is swelling of the body tissues, which doctors call “edema”, occurring mainly in the face (e.g. lips, eyelids), although the extremities and genitals are often affected. Swelling of the internal organs, specifically the mucous membranes of the larynx, nose or tongue, is potentially life threatening as it can cause death by suffocation. More than 50 per cent of HAE patients will experience at least one attack of this type in their lifetime. “Patients are frequently misdiagnosed because HAE symptoms often resemble those of more common conditions. Through 2017 haeday:) we hope to spread the word about HAE, so patients can receive an accurate diagnosis and appropriate medical care,” Mr. Balle Boysen explains: “We are very excited by the level of participation from the HAE national organizations across the globe and hope that the awareness day will make a real difference to lives of HAE patients in the future.” HAE places extraordinary strain on patients, often restricting their ability to lead normal lives. Untreated HAE patients can lose 100 to 150 workdays per year or more. Currently there is no permanent cure for HAE, but treatment options are available to try and prevent attacks from occurring or to treat attacks when they do occur. Various events are taking place across the globe in aid of the global awareness day. Internationally 2017 haeday:) coincides with some 30 patients and supporters – many of who suffer with from HAE – from Africa, Europe, North America, and South America walking part of the historic Camino de Santiago in northern Spain 14-17 May 2017. • Join the official haeday:) o Website at www.haeday.org o Facebook page at www.facebook.com/haeday o Twitter account at www.twitter.com/haeday o YouTube channel at www.youtube.com/haedaychannel • Other sources o HAEi website: www.haei.org o HAE QE (Nederlandse HAE patiënten vereniging) www.hae-qe.nl/ --ENDS--
Pharming announces refinancing of its existing debt by a single US$100 million debt facility on improved commercial terms Repayment of amortising convertible bonds eliminates risk of approximately 24% dilution Leiden, The Netherlands, 16 May 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announces that it has completed a new US$100 million finance agreement with Orbimed Advisors. This has been used to redeem the Amortizing Convertible Bonds due 2017/2018, and to refinance the Company’s senior debt facility with Silicon Valley Bank and Kreos Capital, together with the associated prepayment fees and the legal and other costs of the transaction. The loan, initially structured as a bridge facility will be replaced within 60 days by a full loan agreement with a maturity date of June 2021 under similar terms and conditions as described below. Highlights ? New four year $100m (€91.7 million) Senior Secured Debt facility to refinance debt on more favourable terms to redeem a total of €35.9 million (US$39.1 million) of Amortising Convertible Bonds and refinance US$40 million of Senior Debt. The other terms of the new facility are not being disclosed ? Net effect: o Release of 124.2 million shares reserved against the Amortizing Convertible Bonds, minus just under 9.2 million warrants for Orbimed, eliminates risk of approximately 24% current dilution effect for existing shareholders o Significant reduction of near term cash burn (from amortisations and debt repayments) of approximately €16 million in 2017 and almost €8 million in 2018, which will allow for investment in RUCONEST® commercialisation and pipeline development ? Existing €11.8 million 5 year (December 2021) 8.5% Ordinary Convertible Bonds are unaffected by this transaction. ? No significant effect on Company’s cash balance at present, which stands at €33 million. Dr Sijmen de Vries, CEO of Pharming, commented: “We are delighted to announce that we have been able to improve the December 2016 funding of our RUCONEST® commercial rights acquisition further by refinancing the Senior Debt and redeeming the Amortizing Convertible Bonds on such excellent terms. Orbimed Advisors is one of the world’s leading specialty debt investors in the life science sector, and we are very pleased to have them as a long term partner. 2 This new refinance enables us to remove from the market the likelihood of issue of a substantial part of our authorized share capital (124 million shares) that was tied to the Amortising Convertible Bonds facility. With a conversion price of €0.289, these Bonds might otherwise have been converted into shares at significant discount to the current market price. The net effect on the Company’s balance sheet is significant. We will not be required to make repayments over the next 12 months of almost €3 million per month in cash (or in shares at a discount) on the Amortizing Convertible Bonds, nor to make repayments of almost €1 million per month on the senior debt from December this year until October of next year. This allows us to invest our cash into promoting RUCONEST® and developing our pipeline and facilities, thereby enhancing growth opportunities. This is, therefore, another excellent day for our existing shareholders. We would like to thank our previous lenders, Kreos Capital and Silicon Valley Bank, and the holders of the Amortizing Convertible Bonds, who, by backing us in December 2016, enabled the Company to make the transformational acquisition of the North American commercial rights for RUCONEST®.” Capital Summary Numbers of Shares: Prior to the Transaction Transaction Today Issued share capital (shares) Reserved for: Share Option Schemes Investor Warrants Convertible Bonds: - Amortizing - Ordinary (€11.8 million) Fully Diluted Shares 484,583,475 54,623,675 92,228,283 124,207,613 41,443,662 797,086,708 - - 9,174,372 (124,207,613) - (115,033,241) 484,583,475 54,623,675 101,402,655 - 41,443,662 682,053,467 Authorized Share Capital (shares) Headroom available for issue 800,000,000 2,913,292 115,033,241 800,000,000 117,946,533 % Capital available for use 0.4% 14.7% Further details New Debt Facility ? The Company has signed an agreement with Orbimed Advisors (the Lender) for a US$100 million (€91.7 million), four year debt facility on improved commercial terms. The overall interest rate is approximately 12%, reducing to 11% if the Company achieves net sales in the USA of US$100 million during the term of the loan. 3 ? The loan has been used to redeem the current Amortizing Convertible Bonds due 2017/2018, in an amount of €44.9 million including early repayment fees, and also to refinance the existing senior debt facility in an amount of €43.3 million including early repayment fees. ? As a result of the retirement of the Amortizing Bonds, the 124.2 million shares which were reserved against conversion of the remaining Amortizing Bonds, are no longer reserved for that purpose, and returned to treasury. Net of the shares which will be reserved for the warrants, this is a total of 115.0 million shares (approximately 24% of the issued share capital). The Company has no plans to issue these shares at this time. ? Also as a result of this transaction, the Company’s cash burn will be reduced by the likely amount of cash repayments under the Amortizing Convertible Bonds in the rest of 2017 and in 2018, plus the amount of the cash repayments on the senior debt facility which start in December 2017 and continue through most of the loan period. The net effect in 2017 is expected to be €16.5 million, and the net effect in 2018 is expected to be €7.7 million. This excludes the effects on the Company of any repayments of the Amortizing Convertible Bonds which might have been made in shares. --- Ends ---
MSTERDAM (AFN) - Biotechnoloog Pharming heeft een herfinancieringsfaciliteit gesloten ter waarde van 100 miljoen dollar met Orbimed Advisors. Dat maakte Pharming dinsdag bekend. Klik hier voor meer nieuws en actuele koersinformatie over Pharming Group De faciliteit zal worden gebruikt voor terugbetaling van bestaande obligaties en herfinanciering van de lening van Silicon Valley Bank en Kreos Capital. De overeenkomst met Orbimed, die aanvankelijk als een overbruggingsfaciliteit is opgezet, zal binnen zestig dagen worden vervangen door een leningsovereenkomst met een looptijd tot juni 2021. Volgens Pharming is met deze faciliteit een mogelijke verwatering van 24 procent voor bestaande aandeelhouders voorkomen en is er een aanzienlijke afname van de zogenoemde 'cash burn'. Dat komt volgens het bedrijf ten goede aan de commerciële inspanningen voor Ruconest en verdere ontwikkeling van de pijplijn. Topman Sijmen de Vries van Pharming liet in een reactie weten dat de financieringsregeling met Orbimed moet worden gezien als teken van vertrouwen in de onderneming. Volgens De Vries is Orbimed ,,een grote en vooraanstaande naam'' als het gaat om investeringen in met name de gezondheidssector.
www.orbimed.com/en/about-us Altijd even checken. wie, wat en hoe over van bedrijf.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)